BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

 BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

Shots:

  •  The P-IV AUGUSTUS study involves assessing of Eliquis (apixaban) vs vitamin K antagonists (VKAs) & aspirin vs PBO in 4,614 patients with non-valvular atrial fibrillation (NVAF), acute coronary syndrome (ACS) & undergoing percutaneous coronary intervention (PCI) with P2Y12 inhibitor with or without aspirin
  • The P-IV AUGUSTUS study results: low mortality rate (23.5% vs 27.4% & 26.2% vs 24.7%); ischemic events (6.7% vs 7.1% & 6.5% vs 7.3%); CRNM bleeding (10.5% vs 14.7% & 16.1% vs. 9.0%)
  • Eliquis (apixaban,5mg/2.5mg, q2d) is an oral anticoagulant targeting factor Xa inhibitor to prevent thromboembolic event and has received FDA’s approval on December 28, 2012 & August 21, 2014 for atrial fibrillation & recurring DVT and PE respectively

Click here to read full press release/ article | Ref: BMS | Image: pyss

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post